A randomized clinical trial shows recombinant vaccine improves immune responses in adults with severe obesity, suggesting enhanced protection against influenza.
In adults living with severe obesity, RIV elicited stronger short-term humoral immune responses than an egg-based standard-dose vaccine, suggesting potential additional benefit for influenza prevention in this vulnerable population.
No takes yet. Share an insight, caveat, or question.
Loubet et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: